ATE453382T1 - Pulver zur nasalen verabreichung von wirkstoffen - Google Patents

Pulver zur nasalen verabreichung von wirkstoffen

Info

Publication number
ATE453382T1
ATE453382T1 AT02801894T AT02801894T ATE453382T1 AT E453382 T1 ATE453382 T1 AT E453382T1 AT 02801894 T AT02801894 T AT 02801894T AT 02801894 T AT02801894 T AT 02801894T AT E453382 T1 ATE453382 T1 AT E453382T1
Authority
AT
Austria
Prior art keywords
nasal administration
powder
active ingredients
formulae
present
Prior art date
Application number
AT02801894T
Other languages
English (en)
Inventor
Paolo Colombo
Patrizia Santi
Ruggero Bettini
Pier Catellani
Mariella Artusi
Cecilia Sacchetti
Original Assignee
Univ Parma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Parma filed Critical Univ Parma
Application granted granted Critical
Publication of ATE453382T1 publication Critical patent/ATE453382T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02801894T 2001-10-18 2002-10-17 Pulver zur nasalen verabreichung von wirkstoffen ATE453382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002174A ITMI20012174A1 (it) 2001-10-18 2001-10-18 Polvere per somministrazione nasale di farmaci
PCT/EP2002/011628 WO2003035034A2 (en) 2001-10-18 2002-10-17 Powder for nasal administration of drugs

Publications (1)

Publication Number Publication Date
ATE453382T1 true ATE453382T1 (de) 2010-01-15

Family

ID=11448525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801894T ATE453382T1 (de) 2001-10-18 2002-10-17 Pulver zur nasalen verabreichung von wirkstoffen

Country Status (7)

Country Link
US (1) US20050019411A1 (de)
EP (1) EP1441699B1 (de)
AT (1) ATE453382T1 (de)
AU (1) AU2002357457A1 (de)
DE (1) DE60234945D1 (de)
IT (1) ITMI20012174A1 (de)
WO (1) WO2003035034A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
WO2009052869A1 (en) * 2007-10-26 2009-04-30 Universita' Degli Studi Di Parma Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
WO2017146994A1 (en) * 2016-02-24 2017-08-31 Merck Sharp & Dohme Corp. Controlled agglomeration of micronized drug or drug-excipient mixtures
CN110300588A (zh) * 2017-03-07 2019-10-01 菲利普莫里斯生产公司 可吸入尼古丁调配物及其制造和使用方法
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
EP3962455B1 (de) 2020-05-18 2022-08-31 Orexo AB Neue pharmazeutische zusammensetzung zur wirkstoffabgabe
EP3991573A1 (de) * 2020-11-03 2022-05-04 Patrick Faber Zusammensetzungen zur nasalen applikation
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
TR200001596T2 (tr) * 1997-12-03 2000-12-21 Fujisawa Pharmaceutical Co., Ltd. Yumuşak hap ilaç ve bunun üretim usulü
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e

Also Published As

Publication number Publication date
ITMI20012174A1 (it) 2003-04-18
EP1441699B1 (de) 2009-12-30
EP1441699A2 (de) 2004-08-04
WO2003035034A2 (en) 2003-05-01
DE60234945D1 (de) 2010-02-11
US20050019411A1 (en) 2005-01-27
WO2003035034A3 (en) 2004-03-11
AU2002357457A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
ATE453382T1 (de) Pulver zur nasalen verabreichung von wirkstoffen
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
PT1412384E (pt) Formulação estável de glp-1 modificado
EA200301275A1 (ru) Капсулы для ингаляции
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2004006959A8 (en) Liquid dosage compositions of stable nanoparticulate active agents
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
DE50304868D1 (de) Verwendung von mandelsäurealkylamiden als aromastoffe
SE0103211D0 (sv) New formulations and use thereof
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
MY144036A (en) Liquid pharmaceutical formulations of polonosetron
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
SI1433478T1 (sl) Farmacevtske formulacije za tiroidne hormone in postopki za njihovo pripravo
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
ATE520405T1 (de) Inhalationszusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties